Document is current
Any future updates will be listed below
-
Authors
Brockhurst, J
Cheleuitte-Nieves, C
Buckmaster, C L
Schatzberg, A F
Lyons, D M
- License Information
-
More Information
Article History
Received: 6 October 2014
Revised: 4 February 2015
Accepted: 9 February 2015
First Online: 31 March 2015
Competing interests
: AFS reports equity in Merck, Pfizer, Neurocrine, XHale and Corcept Therapeutics (co-founder). AFS has received lecture fees from Merck and consulted to Takeda/Lundbeck, Pfizer, Depomed and Neuronetics. The remaining authors declare no conflict of interest. All the authors are employed by or were students at Stanford University.
